Warren Wexelman, MD
Cardiovascular Disease · Brooklyn, NYNPI 1477558468
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $298,529 of the $395,806 with a category attached, or 75.4%. 30 manufacturers reported payments, led by Merck at 50.0% of the total. Reporting peaked in 2022 at $108,964 and has fallen 62.7% since, to $40,630 in 2025. Among cardiovascular disease clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 891 payments — averaging $444.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$198K
- AstraZeneca$82K
- Novo Nordisk$43K
- Amgen$41K
- Novartis$21K
- Johnson & Johnson$7K
- plus $5K from 24 others
What the payments were for
- Consulting fees$4,5001%
- Speaking & faculty fees$298,52975%
- Travel & lodging$72,43818%
- Food & beverage$19,9685%
- Education$370%
- Other$3340%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 235 | $197,819 |
| AstraZeneca | 222 | $81,549 |
| Novo Nordisk | 68 | $43,291 |
| Amgen(2 entities) | 102 | $40,643 |
| Novartis | 52 | $21,135 |
| Johnson & Johnson | 50 | $6,703 |
| Lilly USA, LLC | 25 | $642 |
| Pfizer | 20 | $406 |
| Boehringer Ingelheim | 18 | $391 |
| Corcept Therapeutics | 12 | $366 |
| Welch Allyn | 1 | $334 |
| Abbott | 6 | $329 |
| Regeneron Healthcare Solutions, Inc. | 9 | $291 |
| GSK | 10 | $291 |
| Edwards Lifesciences | 11 | $276 |
| Intra-sana Laboratories | 9 | $257 |
| Esperion Therapeutics, Inc. | 9 | $205 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $150 |
| Boston Scientific | 4 | $145 |
| Sanofi-aventis U.S. LLC | 6 | $132 |
| Amarin Pharma, Inc. | 6 | $120 |
| E.r. Squibb & Sons, L.L.C. | 4 | $98 |
| Heartflow, Inc. | 4 | $95 |
| Cequr Corporation | 1 | $25 |
| Exact Sciences | 1 | $23 |
| Bayer | 1 | $21 |
| Kowa Pharmaceuticals America, Inc. | 1 | $21 |
| Xeris Pharmaceuticals, Inc. | 1 | $17 |
| Medtronic | 1 | $17 |
| AbbVie | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$395,806 in reported general payments places this provider in the 95th percentile of 2,302 cardiovascular disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 188 | $224,934 |
| EliquisApixaban | 165 | $161,362 |
| OzempicSemaglutide | 123 | $129,911 |
| MounjaroTirzepatide | 102 | $121,512 |
| XareltoRivaroxaban | 89 | $103,061 |
| BrilintaTicagrelor | 85 | $79,350 |
| Repatha SureclickEvolocumab | 91 | $67,177 |
| JanuviaSitagliptin Phosphate | 54 | $64,405 |
| JardianceEmpagliflozin | 56 | $50,970 |
| RybelsusSemaglutide | 28 | $44,334 |
| EntrestoSacubitril/Valsartan | 38 | $39,935 |
| ProliaDenosumab | 19 | $32,034 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 24 | $19,955 |
| VerquvoVericiguat | 15 | $19,758 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $12,490 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Brilinta, Breztri Aerosphere | $81,549 | $324,239297 claims |
| Novo NordiskOzempic, Rybelsus | $43,291 | $174,245151 claims |
| PfizerEliquis | $406 | $161,362165 claims |
| Lilly USA, LLCMounjaro | $642 | $121,512102 claims |
| Johnson & JohnsonXarelto | $6,703 | $103,06189 claims |
| MerckJanuvia, Verquvo | $197,819 | $84,16369 claims |
| Boehringer IngelheimJardiance | $391 | $50,97056 claims |
| NovartisEntresto | $21,135 | $39,93538 claims |
| AmgenProlia | $40,643 | $32,03419 claims |
| GSKTrelegy Ellipta, Arexvy, Shingrix | $291 | $20,91650 claims |
| AbbVieSynthroid | $16 | $1,93131 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,302 cardiovascular disease providers in New York.
Other cardiovascular disease in Brooklyn
- Ronald WhartonBrooklyn$426K
- Ozgen DoganBrooklyn$290K
- Sergey AyzenbergBrooklyn$157K
- Roger HajjarNew York$5.2M
- Szilard VorosStony Brook$3.7M
- Gregg StoneNew York$2M
- Augustin DelagoAlbany$1.8M
- Philippe GenereuxNew York$1.3M
- Adam RosenbluthNew York$1.1M
- Luigi di BiaseBronx$978K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.